{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:56:24Z","timestamp":1790250984120,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.jbspin.2012.07.018","type":"journal-article","created":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T21:36:09Z","timestamp":1348781769000},"page":"178-182","source":"Crossref","is-referenced-by-count":65,"title":["Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: A report of 16 cases and review of the literature"],"prefix":"10.1016","volume":"80","author":[{"given":"S\u00e9bastien","family":"Ottaviani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Brunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Maurier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ardizzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wendling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislaine","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Dieud\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2012.07.018_bib0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/rheumatology\/kep081","article-title":"An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease","volume":"48","author":"Richette","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0010","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.joca.2008.06.003","article-title":"Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study","volume":"17","author":"Filippucci","year":"2009","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0015","first-page":"2","article-title":"Ultrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition disease","volume":"28","author":"Filippucci","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/ard.2010.139105","article-title":"European League against rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0025","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine update: 2008","volume":"38","author":"Terkeltaub","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0035","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.3748\/wjg.v17.i42.4647","article-title":"Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury","volume":"17","author":"Park","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/sarh.2002.37216","article-title":"Anti-inflammatory agents and renal function","volume":"32","author":"Brater","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jbspin.2009.10.011","article-title":"Anti-IL-1 molecules: new comers and new indications","volume":"77","author":"Molto","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.immuni.2012.01.018","article-title":"Inflammasome activators induce interleukin-1 alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1","volume":"36","author":"Gross","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.semarthrit.2010.03.001","article-title":"Anakinra's efficacy is variable in refractory gout: report of ten cases","volume":"40","author":"Chen","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0065","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0070","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0075","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0080","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jbspin.2009.01.001","article-title":"Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure","volume":"76","author":"Announ","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0085","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.23119","article-title":"Successful treatment of resistant pseudogout with anakinra","volume":"58","author":"McGonagle","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0090","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jbspin.2011.12.017","article-title":"Efficacy of anakinra in articular chondrocalcinosis: report of three cases","volume":"79","author":"Couderc M","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0095","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2010.139360","article-title":"EULAR recommendations for calcium pyrophosphate deposition. Part II: management","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.07.018_bib0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.immunol.16.1.27","article-title":"Interleukin-1 receptor antagonist: role in biology","volume":"16","author":"Arend","year":"1998","journal-title":"Annu Rev Immunol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X12001935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X12001935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T08:01:15Z","timestamp":1542700875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X12001935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1297319X12001935"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2012.07.018","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}